Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Baliforsen (ISIS 598769) in Adults With Myotonic Dystrophy Type 1
NCT02312011Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Dec 2014
- Primary completion
- Jul 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myotonic dystrophy type 1 (DM1) comparing IONIS-DMPKRx with Placebo (2 arms). Primary endpoint: Number of participants with adverse events. Started Dec 2014; status: completed.
02
Drugs
baliforsen
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT02312011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02312011.